UK Regulators Withhold Support for Astra Breast-Cancer Drug (1)

AstraZeneca Plc and Daiichi Sankyo Co.failed to win immediate endorsement for an additional use for their breast cancer medicine from England’s drug-cost regulator, a potential blow to the companies’ efforts to expand sales of one of their most promising therapies.

A committee for the National Institute for Health and Care Excellence said Tuesday that the companies need to provide more information about the benefits of the drug, called Enhertu, in patients with advanced HER2-low breast cancer. The agency acknowledged the drug could provide a major advance for these patients, who have low levels of a protein linked to growth ...